Guardant Health Inc - Asset Resilience Ratio
Guardant Health Inc (GH) has an Asset Resilience Ratio of 5.92% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Guardant Health Inc (GH) strategic investment index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how Guardant Health Inc's Asset Resilience Ratio has changed over time. See Guardant Health Inc (GH) balance sheet quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Guardant Health Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Guardant Health Inc (GH) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $113.47 Million | 5.92% |
| Total Liquid Assets | $113.47 Million | 5.92% |
Asset Resilience Insights
- Limited Liquidity: Guardant Health Inc maintains only 5.92% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Guardant Health Inc Industry Peers by Asset Resilience Ratio
Compare Guardant Health Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
Inoviq Ltd
AU:IIQ |
Diagnostics & Research | 56.29% |
|
Cryosite Ltd
AU:CTE |
Diagnostics & Research | 5.65% |
|
RHYTHM Biosciences Ltd
AU:RHY |
Diagnostics & Research | 2.74% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
Annual Asset Resilience Ratio for Guardant Health Inc (2016–2025)
The table below shows the annual Asset Resilience Ratio data for Guardant Health Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 40.89% | $823.39 Million | $2.01 Billion | +19.72pp |
| 2024-12-31 | 21.17% | $314.44 Million | $1.49 Billion | +19.20pp |
| 2023-12-31 | 1.96% | $35.10 Million | $1.79 Billion | -52.05pp |
| 2022-12-31 | 54.01% | $869.58 Million | $1.61 Billion | +34.03pp |
| 2021-12-31 | 19.98% | $440.55 Million | $2.20 Billion | -22.36pp |
| 2020-12-31 | 42.34% | $961.90 Million | $2.27 Billion | +2.91pp |
| 2019-12-31 | 39.43% | $379.57 Million | $962.53 Million | -7.96pp |
| 2018-12-31 | 47.40% | $278.42 Million | $587.40 Million | +3.94pp |
| 2017-12-31 | 43.46% | $149.04 Million | $342.94 Million | -9.44pp |
| 2016-12-31 | 52.90% | $61.66 Million | $116.56 Million | -- |
About Guardant Health Inc
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tu… Read more